Exchange: NASDAQ·Updated 07:58 PM EDT

PGEN News

News
all
press releases
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
Zacks
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
Zacks
More News
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.
Zacks
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
Zacks
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.
Zacks
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
Healthcare stocks like Abbott Laboratories offer low-beta exposure as rate hike fears and inflation keep markets volatile.
Zacks
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
TMO, CRCT and SHOP delivered strong gains as Zacks highlighted standout performers across its research portfolios.
Zacks
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Zacks
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
Zacks
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.
Zacks

Advertisement|Remove ads.